30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Bacterin

$8.4MM, +7%

  • OsteoSponge bone void filler represents ~60% of trailing revenue, OsteoSelect DBM putty ~17%
  • In early 4Q, launched 3Demin (demineralized) line for procedures requiring larger volume of bone graft; Boat and Strip configurations targeted for complex spine, to compete with Medtronic and Stryker (including synthetic constructs and allografts)
  • Planning to grow field sales team by 40% in 2015 (35 currently)
  • Procedure revenue “north of $2,000 per procedure”